 "TTK, PSG Institute, two US universities to collaborate for heart valves")
TTK Healthcare Ltd will partner with PSG Institute of Medical Sciences and Research (PSG IMSR), Coimbatore, Colorado State University (CSU) and The Ohio State University (OSU), to develop low cost prosthetic heart valves for India. The project is funded through a grant from National Institutes of Health (NIH).
The research partners aims to develop low-cost replacement heart valves that promise to be superior to current mechanical and tissue-based heart valves and reduce patients need for medication to prevent blood clots.
As industry partner, TTK Healthcare will commercialise technology on the replacement valves, when it is developed. The consortium is supported by a two year joint grant from the National Institutes of Health (NIH) in US and Department of Biotechnology in India.
Dr Chandrasekar (Chandra) from CSU will lead the management of this international collaboration that will work on developing a novel heart valves made from plastic materials to address the problems associated with rheumatic heart valve disease, which is the most common form of valve disease in developing nations.
While patients who receive mechanical heart valves must remain on lifelong medication to prevent blood clotting, the bio-prosthestic valves, usually made from animal tissue, are prone to hardening over time and do not last more than 10-15 years, which is not suitable for young patients with rheumatic valve disease for various reasons, said Principal Investigator Lakshmi Prasad Dasi. The artificial heart valves to be developed in this project will be made from flexible plastic materials containing hyaluronan, a molecule found throughout the body and in the natural heart valve tissues.
The entire pre-clinical trials will take place in India with involvement from TTK Healthcare, the manufacturer of the TTK Chitra Heart Valve.
"If successful, TTK Healthcare Ltd will seriously consider investing in commercialisation of the technology," said in the release.
In addition to implantable low-cost heart valves, the team hopes their innovative strategy can be translated and engineered as a trans-catheter heart valves, thereby eliminating the need for open heart surgery.
The research partners aims to develop low-cost replacement heart valves that promise to be superior to current mechanical and tissue-based heart valves and reduce patients need for medication to prevent blood clots.
As industry partner, TTK Healthcare will commercialise technology on the replacement valves, when it is developed. The consortium is supported by a two year joint grant from the National Institutes of Health (NIH) in US and Department of Biotechnology in India.
Dr Chandrasekar (Chandra) from CSU will lead the management of this international collaboration that will work on developing a novel heart valves made from plastic materials to address the problems associated with rheumatic heart valve disease, which is the most common form of valve disease in developing nations.
While patients who receive mechanical heart valves must remain on lifelong medication to prevent blood clotting, the bio-prosthestic valves, usually made from animal tissue, are prone to hardening over time and do not last more than 10-15 years, which is not suitable for young patients with rheumatic valve disease for various reasons, said Principal Investigator Lakshmi Prasad Dasi. The artificial heart valves to be developed in this project will be made from flexible plastic materials containing hyaluronan, a molecule found throughout the body and in the natural heart valve tissues.
The entire pre-clinical trials will take place in India with involvement from TTK Healthcare, the manufacturer of the TTK Chitra Heart Valve.
"If successful, TTK Healthcare Ltd will seriously consider investing in commercialisation of the technology," said in the release.
In addition to implantable low-cost heart valves, the team hopes their innovative strategy can be translated and engineered as a trans-catheter heart valves, thereby eliminating the need for open heart surgery.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%